<ENAMEX TYPE="ORGANIZATION">Allergan Inc.</ENAMEX> said that two shareholder lawsuits were filed in a federal court in <ENAMEX TYPE="LOCATION">Philadelphia</ENAMEX> alleging misstatements of material facts in connection with the recent spinoff of the eye and skin-care company.
<ENAMEX TYPE="ORGANIZATION">Allergan</ENAMEX>, <ENAMEX TYPE="LOCATION">Irvine</ENAMEX>, <ENAMEX TYPE="LOCATION">Calif.</ENAMEX>, was spun off in July from <ENAMEX TYPE="ORGANIZATION">Smithkline Beckman Corp.</ENAMEX> as part of the recent merger of <ENAMEX TYPE="ORGANIZATION">Smithkline</ENAMEX> and <ENAMEX TYPE="ORGANIZATION">Beecham Group PLC</ENAMEX>. The two combined pharmaceuticals companies were renamed <ENAMEX TYPE="ORGANIZATION">Smithkline Beecham</ENAMEX>. <ENAMEX TYPE="ORGANIZATION">Smithkline Beecham</ENAMEX> and <ENAMEX TYPE="PERSON">Gavin Herbert</ENAMEX>, <ENAMEX TYPE="LOCATION">Allergan</ENAMEX>'s chairman and chief executive officer, were named defendants in the suits, which allege that false statements were made or material facts were omitted about <ENAMEX TYPE="LOCATION">Allergan</ENAMEX>'s business and prospects.
The suits seek class-action status and unspecified damages.
<ENAMEX TYPE="ORGANIZATION">Allergan</ENAMEX> denied the allegations and said it will ``vigorously contest the actions.'' In <ENAMEX TYPE="LOCATION">Philadelphia</ENAMEX>, a spokesman for <ENAMEX TYPE="ORGANIZATION">Smithkline Beecham</ENAMEX> said the company didn't have anything to add to <ENAMEX TYPE="LOCATION">Allergan</ENAMEX>'s comment.
